

Sample content

Non-Small-Cell Lung Cancer

Disease Landscape & Forecast

Published: August 2024

About Disease Landscape & Forecast

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.



What are the sizes of the diagnosed, drug-treatable, and/or drug-treated populations?



What is the current treatment landscape?



What products are in development, and what is their launch potential and future positioning?



What is the market outlook of sales and patient share for the next 10 years?



What are the drivers and constraints of market growth, and what events will most impact the market's trajectory?



What unmet needs and opportunities exist?

Methodology and scope

Market forecast

- **Forecast:** Annualized drug-level sales and patient share of key NSCLC therapies from 2023 to 2033, segmented by brands/generics.
- **Epidemiology:** Total, diagnosed, and drug-treated prevalent cases of NSCLC by country.
- **Market segmentations:** By histology, disease stage, resectability, and line of therapy.
- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Interviews with 38 thought-leading NSCLC specialists across the G7.
- Data and insights leveraged from physician surveys conducted by Clarivate in NSCLC to model current and future market dynamics.

Geography



United States



EU5




Japan

Key therapies covered





Phase 3	<ul style="list-style-type: none">• Volrustomig (AstraZeneca)• Datopotamab deruxtecan (Daiichi Sankyo / AstraZeneca)• Lazertinib (Yuhan Corporation / Johnson & Johnson)
Marketed	<ul style="list-style-type: none">• Pembrolizumab (Keytruda)• Durvalumab (Imfinzi)• Atezolizumab (Tecentriq)• Nivolumab (Opdivo)• Osimertinib (Tagrisso)• Alectinib (Alecensa)• Lorlatinib (Lorbrena / Lorviqua)

Report table of contents

1. **Executive Summary**
2. **Key Updates**
3. **Market Forecast**
 - Key takeaways
 - Market drivers and constraints
 - Segment-specific trends
5. **Epidemiology**
 - Key takeaways
 - Epidemiology populations
 - Diagnosed incident cases
 - Stage distribution of NSCLC
 - Recurrent incident cases of NSCLC
 - Drug-treatable and drug-treated populations
6. **Current Treatment**
 - Key takeaways
 - Treatment for NSCLC
 - Key current therapies
7. **Emerging Therapies**
 - Key takeaways
 - Key emerging therapies
 - Unmet need in NSCLC
8. **Drug Pipeline** (powered by Cortellis)
9. **Appendix**



Report format

-  **In-depth written analyses** available on Clarivate's Insights Platform or as a PDF download
-  Succinct **Executive Summary** deck
-  **Market Forecast Assumptions** (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)
-  **Market Forecast Dashboard** (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)

Sample content


Question answered

What are the expected sales of key drugs used to treat NSCLC in the G7 markets over the next 10 years?

Source: Clarivate

© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

SALES	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Immunotherapy drugs	\$1,100.00	\$1,150.00	\$1,200.00	\$1,250.00	\$1,300.00	\$1,350.00	\$1,400.00	\$1,450.00	\$1,500.00	\$1,550.00	\$1,600.00
Targeted therapy drugs	\$800.00	\$820.00	\$840.00	\$860.00	\$880.00	\$900.00	\$920.00	\$940.00	\$960.00	\$980.00	\$1,000.00
Chemotherapy drugs	\$500.00	\$480.00	\$460.00	\$440.00	\$420.00	\$400.00	\$380.00	\$360.00	\$340.00	\$320.00	\$300.00
Supportive care drugs	\$200.00	\$210.00	\$220.00	\$230.00	\$240.00	\$250.00	\$260.00	\$270.00	\$280.00	\$290.00	\$300.00
Other drugs	\$100.00	\$110.00	\$120.00	\$130.00	\$140.00	\$150.00	\$160.00	\$170.00	\$180.00	\$190.00	\$200.00



What are the current treatment paradigms in NSCLC?




Sample content

Question answered

When are the key novel therapies expected to launch for NSCLC over the next 10 years?


Major-market sales of emerging drugs in NSCLC: 2023-2033



Sample content

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?





About Clarivate

Disease Intelligence and Analytics

Disease intelligence you can trust



Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.



Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.



Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.



Assess and prioritize opportunities

Evaluate market potential for your assets – and those of your competitors – and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.



Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.



Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

Find out more

Learn more about how Clarivate can help you maximize your market share:

clarivate.com/products/biopharma/portfolio-strategy-business-development



Think forward™

Contact our experts today:
healthcare.support@clarivate.com
clarivate.com

About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2024 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.